D-0562-2024 Class II

Recalled by Breckenridge Pharmaceutical, Inc — Berlin, CT

Recall Details

Product Type
Drugs
Report Date
June 26, 2024
Initiation Date
May 17, 2024
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
165,678, 90-count bottles

Product Description

Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Distribution Pattern

Nationwide in the USA

Code Information

Lot #: 230035C, Exp. date 11/30/2025; 230101C, Exp. date 12/31/2025